Deferred Tax Assets, Valuation Allowance of Kura Oncology, Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Kura Oncology, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • Kura Oncology, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $363,890,000, a 30% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Kura Oncology, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $363,890,000 +$85,031,000 +30% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q4 2024 $278,859,000 +$54,678,000 +24% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q4 2023 $224,181,000 +$47,853,000 +27% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q4 2022 $176,328,000 +$43,122,000 +32% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q4 2021 $133,206,000 +$40,683,000 +44% 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q4 2020 $92,523,000 +$30,098,000 +48% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q4 2019 $62,425,000 +$18,826,000 +43% 31 Dec 2019 10-K 24 Feb 2021 2020 FY
Q4 2018 $43,599,000 +$17,748,000 +69% 31 Dec 2018 10-K 25 Feb 2020 2019 FY
Q4 2017 $25,851,000 +$4,397,000 +20% 31 Dec 2017 10-K 05 Mar 2019 2018 FY
Q4 2016 $21,454,000 +$11,139,000 +108% 31 Dec 2016 10-K 12 Mar 2018 2017 FY
Q4 2015 $10,315,000 +$8,907,000 +633% 31 Dec 2015 10-K 14 Mar 2017 2016 FY
Q4 2014 $1,408,000 +$1,348,900 31 Dec 2014 10-K 17 Mar 2016 2015 FY
Q4 2013 $59,100* -$49,340,900 31 Dec 2013 10-K 27 Feb 2015 2014 FY
Q4 2012 $49,400,000 +$9,200,000 +23% 31 Dec 2012 10-K 31 Mar 2014 2013 FY
Q4 2011 $40,200,000 31 Dec 2011 10-K 28 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.